Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia

Leukemia

Volumn 28, Issue 10, 2014, Pages 1969-1977

  Walter, R B ^a,b   Laszlo, G S ^a   Lionberger, J M ^a,e   Pollard, J A ^a,c   Harrington, K H ^a   Gudgeon, C J ^a   Othus, M ^a   Rafii, S ^d   Meshinchi, S ^a,c   Appelbaum, F R ^a,b   Bernstein, I D ^a,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CD33 ANTIGEN; CD34 ANTIGEN; GEMTUZUMAB OZOGAMICIN; CD33 PROTEIN, HUMAN; CORE BINDING FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL EXPANSION; CELL GROWTH; CELL HETEROGENEITY; CELL HYPOXIA; CELL ISOLATION; CELL MATURATION; CELL POPULATION; CLINICAL ARTICLE; COCULTURE; COLONY FORMING UNIT GM; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; KARYOTYPE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; STEM CELL CULTURE; STEM CELL EXPANSION; X CHROMOSOME INACTIVATION; CELL SEPARATION; CYTOLOGY; FLOW CYTOMETRY; GENETICS; HEMATOPOIETIC SYSTEM; METABOLISM; MUTATION; PROGNOSIS;

ANTIGENS, CD34; CELL HYPOXIA; CELL SEPARATION; COCULTURE TECHNIQUES; CORE BINDING FACTORS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HEMATOPOIETIC SYSTEM; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; RECEPTORS, ARYL HYDROCARBON; SIALIC ACID BINDING IG-LIKE LECTIN 3;

EID: 84921744291     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.107     Document Type: Article

References (51)

1. Welch JS, Link DC. Genomics of AML: clinical applications of next-generation sequencing. Hematology Am Soc Hematol Educ Program 2011; 2011: 30-35
2. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100(Suppl 1): 11842-11849
3. Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. Clin Cancer Res 2007; 13: 3439-3442
4. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807
5. Lane SW, Gilliland DG. Leukemia stem cells. Semin Cancer Biol 2010; 20: 71-76
6. Majeti R. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 2011; 30: 1009-1019
7. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood 2012; 119: 6198-6208
8. Fialkow PJ, Singer JW, Raskind WH, Adamson JW, Jacobson RJ, Bernstein ID et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987; 317: 468-473
9. Bernstein ID, Singer JW, Andrews RG, Keating A, Powell JS, Bjornson BH et al. Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 1987; 79: 1153-1159
10. Bernstein ID, Singer JW, Smith FO, Andrews RG, Flowers DA, Petersens J et al. Differences in the frequency of normal and clonal precursors of colony-forming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood 1992; 79: 1811-1816
11. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481: 506-510
12. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090-1098
13. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Sci Transl Med 2012; 4: 149ra118
14. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 2012; 150: 264-278
15. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest 2011; 121: 384-395
16. Vargaftig J, Taussig DC, Griessinger E, Anjos-Afonso F, Lister TA, Cavenagh J et al. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used. Leukemia 2012; 26: 858-860
17. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 2008; 112: 568-575
18. Taussig DC, Vargaftig J, Miraki-Moud F, Griessinger E, Sharrock K, Luke T et al. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction. Blood 2010; 115: 1976-1984
19. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086-1093
20. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737
21. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL et al. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proc Natl Acad Sci USA 2011; 108: 5009-5014
22. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 2011; 19: 138-152
23. Horton SJ, Huntly BJ. Recent advances in acute myeloid leukemia stem cell biology. Haematologica 2012; 97: 966-974
24. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood 1999; 94: 1761-1772
25. Rombouts WJC, Blokland I, Löwenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-683
26. Rombouts WJC, Martens ACM, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia 2000; 14: 889-897
27. Lumkul R, Gorin NC, Malehorn MT, Hoehn GT, Zheng R, Baldwin B et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia 2002; 16: 1818-1826
28. Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE et al. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 2004; 22: 188-201
29. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006; 107: 1166-1173
30. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR et al. A robust xenotransplantation model for acute myeloid leukemia. Leukemia 2009; 23: 2109-2117
31. Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106: 4086-4092
32. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983; 62: 124-132
33. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984; 8: 521-534
34. Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986; 68: 1030-1035
35. Andrews RG, Singer JW, Bernstein ID. Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med 1989; 169: 1721-1731
36. Bernstein ID, Andrews RG, Berenson R, Bensinger W, Singer JW, Buckner CD. Isolation of human hematopoietic stem cells. In: Champlin RE, Gale RP (eds). New Strategies in Bone Marrow Transplantation. Wiley-Liss: New York, 1991, pp 201-207
37. Robertson MJ, Soiffer RJ, Freedman AS, Rabinowe SL, Anderson KC, Ervin TJ et al. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992; 79: 2229-2236
38. Bock TA. Assay systems for hematopoietic stem and progenitor cells. Stem Cells 1997; 15(Suppl 1): 185-195
39. Johnston DL, Meshinchi S, Opheim KE, Pallavicini MG, Feusner J, Woods WG et al. Progenitor cell involvement is predictive of response to induction chemotherapy in paediatric acute myeloid leukaemia. Br J Haematol 2003; 123: 431-435
40. Pollard JA, Alonzo TA, Gerbing RB, Woods WG, Lange BJ, Sweetser DA et al. FLT3 internal tandem duplication in CD34/CD33-precursors predicts poor outcome in acute myeloid leukemia. Blood 2006; 108: 2764-2769
41. Uchida T, Ohashi H, Aoki E, Nakahara Y, Hotta T, Murate T et al. Clonality analysis by methylation-specific PCR for the human androgen-receptor gene (HUMARA-MSP). Leukemia 2000; 14: 207-212
42. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010; 329: 1345-1348
43. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010; 6: 251-264
44. Chen GL, Prchal JT. X-linked clonality testing: interpretation and limitations. Blood 2007; 110: 1411-1419
45. Grimwade D, Enver T. Acute promyelocytic leukemia: where does it stem from? Leukemia 2004; 18: 375-384
46. Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ et al. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia 2013; 27: 852-860
47. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789-4796
48. Muto A, Mori S, Matsushita H, Awaya N, Ueno H, Takayama N et al. Serial quantification of minimal residual disease of t(8;21) acute myelogenous leukaemia with RT-competitive PCR assay. Br J Haematol 1996; 95: 85-94
49. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97: 7521-7526
50. Burnett AK, Hills RK, Milligan D, Kjeldsen L, Kell J, Russell NH et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29: 369-377
51. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D, Bastie JN et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379: 1508-1516.